All articles by Frankie Fattorini

Frankie Fattorini

Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.

How Pfizer management outplayed activist investor Starboard

Amidst dwindling share prices and widespread criticism, Pfizer CEO Albert Bourla appears to have withstood an attempted ousting by activist…
New study finds obesity costs US industry $347bn a year

A new study published in Nature Nutrition & Diabetes estimates the economic burden associated with obesity on major US industries…
Worldwide 2024 elections pose pivotal shifts in life sciences and healthcare

The outcomes of this year’s US, EU, and UK elections and their downstream effects will lead to drastic changes to…
Are dry powder inhalers the key to sustainable respiratory care?

In a bid to improve the pharma sector’s drive to cut down greenhouse emissions, several companies are advancing dry powder…
Minister for Science champions partnerships with private clinical sector in UK

Lord Patrick Vallance has emphasised plans for a close collaboration between the government and private sector, in line with the…

Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA

Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like…
Pfizer boasts over 30% increase in Q3 revenues against previous year

Pfizer has reported strong revenues in its latest earnings report, noting increased revenues over Q3 2023 largely due to sales…
Arrivo targets major depressive disorder in females after early efficacy data

Arrivo BioVentures’ SIRT6 activator SP-624 has been found to significantly reduce symptoms of major depressive disorder (MDD), but only in…
J&J’s Darzalex combination gains expanded label for multiple myeloma in Europe

The European label for Johnson and Johnson Innovation Medicine’s (J&J) Darzalex (daratumumab) has been expanded to include patients with newly…
A slow start for self-amplifying mRNA vaccines

A year after bursting onto the scene amid the RNA renaissance, scientific challenges and regulatory resistance have held back self-amplifying…